In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia

By La Rosee P.   Johnson K.   O'Dwyer M.E.   Druker B.J.  

Experimental Hematology, Vol. 30, Iss. 7, 2002-07 ,pp. : 729-737

Elsevier

Access to resources Recommend Favorite

Cytogenetic response to autografting in chronic myelogenous leukemia correlates with the amount of BCR-ABL positive cells in the graft - effect on remission duration and survival: Cancer and Leukemia Group B Study 8583

By Corsetti M.T.   Lerma E.   Dejana A.   Cavaliere M.   Figari O.   Vassallo F.   Abate M.   Luchetti S.   Piaggio G.   Parodi C.   Pira G.L.   Manca F.   Carella A.M.  

Experimental Hematology, Vol. 28, Iss. 1, 2000-01 ,pp. : 104-111

Elsevier

Access to resources Recommend Favorite

Unusual location of BCR-ABL1 fusion sequences in a chronic myeloid leukemia patient

By Zámečníkova Adriana   Al Bahar Soad   Pandita Ramesh  

Hematology, Vol. 17, Iss. 6, 2012-11 ,pp. : 321-324

Maney Publishing

Access to resources Recommend Favorite

Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib

By Chahardouli Bahram   Zaker Farhad   Mousavi Seied Asadollah   Saffari Zeinab   Nadali Fatemeh   Ostadali Mohammadreza   Ghadimi Habibeh   Alimoghaddam Kamran   Ghavamzade Ardeshir   Rostami Shahrbano  

Hematology, Vol. 18, Iss. 6, 2013-11 ,pp. : 327-332

Maney Publishing

Access to resources Recommend Favorite

Reconsideration of BCR‐ABL protein flow cytometric immunobead assay: how potent to diagnose and monitor chronic myeloid leukemia?

By  

International Journal Of Laboratory Hematology, Vol. 37, Iss. 5, 2015-10 ,pp. : 723-728

John Wiley & Sons Inc

Access to resources Recommend Favorite